Company Overview
About Clasp Therapeutics
Clasp Therapeutics is a clinical-stage immuno-oncology company developing precision T cell engagers (TCEs) that direct the immune system to destroy solid tumors harboring common oncogenic driver mutations. Unlike first-generation TCEs that target proteins shared between tumor and healthy cells, Clasp''s bispecific antibodies recognize tumor-specific peptide-HLA complexes — molecular fingerprints unique to cancer cells created by mutated proteins.
Business Model & Competitive Advantage
The company''s lead program, CLSP-1025, targets the p53R175H mutant peptide presented by HLA-A*02:01, the most prevalent p53 mutation in solid tumors including gastrointestinal, lung, and gynecological cancers. CLSP-1025 is being evaluated in the Phase 1 GUARDIAN-101 dose escalation study, making it the first tumor-specific TCE to enter clinical development. Clasp has also dosed its first patient in this trial.
Competitive Landscape 2025–2026
Clasp''s platform is designed to address the fundamental challenge of solid tumor immunotherapy — achieving tumor-specific cytotoxicity without on-target, off-tumor toxicity to healthy tissue — through its proprietary mutant peptide-HLA targeting approach.
Key Differentiators
Strong Challenger
Clasp Therapeutics is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.
Frequently Asked Questions
Similar Brands
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Compare Clasp Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Clasp Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Clasp Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Clasp Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →